The Association Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes
Carrie R. Wong, Joseph K. Lim – 7 September 2018
Issue Information
7 September 2018
Dipeptidyl Peptidase‐4 Is a Pro‐Recovery Mediator During Acute Hepatotoxic Damage and Mirrors Severe Shifts in Kupffer Cells
Nádia Duarte, Inês Coelho, Denys Holovanchuk, Joana Inês Almeida, Carlos Penha‐Gonçalves, Maria Paula Macedo – 7 September 2018 – Dipeptidyl peptidase‐4 (DPP‐4 or clusters of differentiation [CD]26) is a multifunctional molecule with established roles in metabolism. Pharmacologic inhibition of DPP‐4 is widely used to improve glycemic control through regulation of the incretin effect. Colaterally, CD26/DPP‐4 inhibition appears to be beneficial in many inflammatory conditions, namely in delaying progression of liver pathology.
Pitfalls in Gd‐EOB‐DTPA–Enhanced Liver Magnetic Resonance Imaging With an Emphasis on Nontumorous Lesions
Yedaun Lee, So Yeon Kim, Seung Soo Lee, Seong Ho Park, Kyoung Won Kim, Jae Ho Byun, Moon‐Gyu Lee – 7 September 2018
Viability Criteria for Functional Assessment of Donor Livers During Normothermic Machine Perfusion
Otto B. van Leeuwen, Vincent E. de Meijer, Robert J. Porte – 7 September 2018
Liver Disease in Cystic Fibrosis: Illuminating the Black Box
Carla Colombo, Gianfranco Alicandro – 6 September 2018
A Rare Nonsense Mutation in the Glucokinase Regulator Gene Is Associated With a Rapidly Progressive Clinical Form of Nonalcoholic Steatohepatitis
Carlos J. Pirola, Diego Flichman, Hernán Dopazo, Tomas Fernández Gianotti, Julio San Martino, Cristian Rohr, Martin Garaycoechea, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian – 5 September 2018 – We report on the presence of a rare nonsense mutation (rs149847328, p.Arg227Ter) in the glucokinase regulator (GCKR) gene in an adult patient with nonalcoholic fatty liver disease (NAFLD), morbid obesity, and type 2 diabetes; this patient developed a progressive histological form of the disease.
Whole‐Exome Sequencing Study of Extreme Phenotypes of NAFLD
Sarah E. Kleinstein, Matthew Rein, Manal F. Abdelmalek, Cynthia D. Guy, David B. Goldstein, Anna Mae Diehl, Cynthia A. Moylan – 5 September 2018 – Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH), and advanced stage fibrosis suffer increased risk for complications such as cirrhosis, hepatic decompensation, and liver cancer.
LiverLearning®: 2018 Webinar: Unraveling the New UNOS Liver Allocation Policy
The new UNOS organ allocation policy is scheduled to go into effect in December 2018. Work your way through the changes and challenges with the Chair of the AASLD Liver Transplantation SIG and Editor-in-Chief of Liver Transplantation in this first of a series of webinars brought to you by a collaboration of the SIG and journal.Paul Martin (Moderator) Paul Martin MD, FAASLD is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, USA.